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tionship between production of abnormal COL IV chains andCOL4A3/COL4A4 mutations: From familial hematuria to au-
dominant expression of a continuous spectrum of phenotypes,tosomal-dominant or recessive Alport syndrome.
from ATS to BFH.Background. Mutations of the type IV collagen COL4A5
gene cause X-linked Alport syndrome (ATS). Mutations of
COL4A3 and COL4A4 have been reported both in autosomal-
recessive and autosomal-dominant ATS, as well as in benign
Alport syndrome (ATS) is a progressive clinically andfamilial hematuria (BFH). In the latter conditions, however,
genetically heterogeneous nephropathy often associatedclinical features are less defined, few mutations have been re-
ported, and other genes and non-genetic factors may be involved. with deafness and/or ocular lesions, and characterized
Methods. We analyzed 36 ATS patients for COL4A3 and by changes of the type IV collagen alpha3/alpha4/alpha5
COL4A4 mutations by polymerase chain reaction–single strand network of the glomerular basement membrane (GBM).conformational polymorphism (PCR-SSCP) and direct se-
Any of the genes encoding these three chains may bequencing. Sporadic patients who had tested negative for
involved. In the common X-linked type (MIM # 301050),COL4A5 mutations were included with typical cases of autoso-
mal recessive ATS to secure a better definition of the pheno- Barker et al [1] and several subsequent studies have
type spectrum. detected COL4A5 mutations in 50 to 60% of cases [2,
Results. We identified seven previously undescribed COL4A3
3; reviewed in 4], and in 85 to 90% with more sensitivemutations: in two genetic compounds and three heterozygotes,
techniques [5, 6]. These results indicate that COL4A5 isand one in COL4A4. In agreement with the literature, some
of the mutations of compound heterozygotes were associated the only gene responsible for X-linked ATS. Mutations
with microhematuria in healthy heterozygous relatives. The of either COL4A3 or COL4A4 on chromosome 2q have
mutations of heterozygous patients are likely dominant, since been found in homozygous or compound heterozygous
no change was identified in the second allele even by sequenc-
state in autosomal-recessive ATS (MIM # 203780) [7–10],ing, and they are predicted to result in shortened or abnormal
and in heterozygous state in benign familial hematuriachains with a possible dominant-negative effect. In addition,
both genes showed rare variants of unclear pathogenicity, and (BFH, MIM # 141200) [9–11]. Lastly, a COL4A3 muta-
common polymorphisms that are shared in part with other tion has recently been identified in a single large family
populations. with autosomal-dominant ATS (MIM # 104200) that had
Conclusions. This study extends the mutation spectrum of
been previously linked to the COL4A3/COL4A4 locusCOL4A3 and COL4A4 genes, and suggests a possible rela-
[12, 13]. We now report detection of eight novel muta-
tions in six out of 36 Italian families in a comprehensive
1I.L. and P.P. equally contributed to this work. mutation screening of COL4A3 and COL4A4.
Key words: benign familial hematuria, collagen IV, inherited nephrop-
athy, X-linked ATS, collagen IV genes.
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Table 1. Clinical features of the 36 probands one in the COL4A4 and five in the COL4A3 genes, all in
heterozygous state and previously undescribed (TablesAR and sporadic cases
2 and 5). Several rare variants of unclear pathogenicMales Females Total AD probands
significance and a number of common polymorphisms
N probands 14 16 30 6
also were found (Tables 3, 4, 6 and 7). In the six probandsMean age years 22.3 18.2 20.1 33.2
ESRD 6 4 10/30 3/6 with one identified mutation direct sequencing was per-
Mean ESRD age years 24.2 24.2 24.2 39 formed to look for further mutations. This characterized
Parents’ consanguinity 2 0 2/30 0
the second allele in two probands (PAR and NCL), whoHypoacusia 7 8 15/30 2/6
Proteinuria 9 13 22/30 3/6 both displayed a mutation in exon 37 of COL4A3. Thus,
Ocular lesions 3 3 6/30 1/6 four mutations were found in two genetic compound
ESRD is end-stage renal disease. probands, both belonging to the group of autosomal-
recessives, whereas in four probands (one autosomal-
dominant, two sporadic and one adopted), there was only
one mutated allele in heterozygous state. Figure 1 showsanalysis of COL4A5 [3] (Table 1). Twelve appeared to
have autosomal-recessive ATS, six exhibited apparent the phenotype and mutation status of the six families.
autosomal-dominant inheritance with father-to-son trans-
COL4A3 changesmission, and 18 were sporadic cases. Consanguinity was
present in two families. Average age of progression to Proband PAR is a compound heterozygote for a non-
end-stage renal disease (ESRD) was 24.2 years in those sense mutation (R1037X) and a ATG→TTG change in
with autosomal-recessive ATS, and 39 years in those the start codon, which probably precludes the synthe-
with autosomal-dominant ATS. Hearing loss was present sis of alpha3(IV) chain (Figs. 1 and 2; Table 2). She
in 17 of 36 probands. is a 14-year-old girl with microhematuria, proteinuria,
chronic renal failure (CRF; blood creatinine 1.5 mg%)
Molecular analysis and deafness. At one year of age she had an episode
All the COL4A3 and COL4A4 exons were amplified of macrohematuria. Electron microscopy of the renal
using primers and polymerase chain reaction (PCR) con- biopsy performed at age three showed splitting of the
ditions described by Boye et al for COL4A4 [9] and by GBM, suggesting a diagnosis of ATS. Slow progressive
Heidet et al for COL4A3 [10]. For exon 39 of COL4A4, renal failure became apparent in adolescence. The fa-
the following new primers were used: forward 5-AGT ther, now aged 40, carries the R1037X mutation and has
ATTAATTCTGTTTTCCCCATT-3; reverse 5-GGGC persistent microhematuria, but normal renal function
AAAGCATGCTACAGCTT-3. The following internal (blood creatinine 1.1 mg%). The mother, aged 33, carries
primers designed on exonic sequences (underlined) were the start codon mutation and does not display either
used: COL4A3 gene, exon 17 reverse 5-ATTACCT microhematuria or other signs of ATS.
TAATGCCATATTC-3, exon 25 reverse 5-TTCACT Proband NCL is a genetic compound for an in-frame
CCCGGAGTT-3; COL4A4 gene, exons 2, 42, 44 are 27 bp deletion in exon 39 (3386del27), causing the loss
in Boye et al [9]. Silver staining, single-strand conforma- of nine amino acids in the collagenous domain, and for
tional polymorphism (SSCP) was performed using either a frame-shift insertion (3209insA) in exon 37. She is a
a Genephor apparatus (Pharmacia Amersham, Little 17-year-old girl with CRF (blood creatinine 2 mg%),
Braunschweig, Germany) or vertical polyacrylamide gel bilateral mixed hearing loss and delayed growth. Micro-
electrophoresis (PAGE). All shifts were confirmed on a hematuria and proteinuria are reported since the age of
second PCR product. Direct sequencing of the purified five months, and one episode of macrohematuria at seven
PCR products was performed in both directions (PE Big months. A renal biopsy at age 13 revealed GBM thick-
dye terminator cycle sequencing kit) on an ABI 377A
ening and splitting, suggesting a diagnosis of ATS. One
Automated Sequencer and analyzed with the Genescan
sister aged nine, with microhematuria (blood creatininesoftware. All exons where mutations or rare variants
0.4 mg%) and one macrohematuria episode at age two,were identified in one patient were determined in ten
has the same compound genotype, while a dizygoticadditional ATS probands and in 50 healthy controls.
co-twin is homozygous for the normal sequence. TheReference nucleotide sequences in the GDB database
father, now aged 43, carries the 3386del27 mutation,were: COL4A3, 128351; COL4A4, 132673. Nucleotides
shows microhematuria with some macrohematuria epi-were numbered starting from the A of the initiator co-
sodes, and has normal renal function (blood creatininedon, in accordance with the codified nomenclature [14].
0.9 mg%) and normal audiogram. The mother is a non-
symptomatic carrier of the 3209insA mutation. She does
RESULTS not show microhematuria or proteinuria, although she
had a left nephrectomy due to hydronephrosis conse-Single-strand conformational polymorphism analysis
of the 36 probands detected six pathogenic mutations, quent to stenosis of the ureteropelvic junction. An appar-
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Fig. 1. Families with identified COL4A3 and
COL4A4 mutations. Mutations are indicated
below or above each individual; all affect the
COL4A3 gene, except for G448S in family
ZIL, which affects COL4A4. Abbreviation is:
W, wild type allele. Symbols are: striped sym-
bols, microhematuria only; black symbols, mi-
crohematuria plus proteinuria or hypacusis or
chronic renal failure.
ently autosomal dominant form of microhematuria seg- She began to suffer from a relapsing steroid-resistant
nephrotic syndrome at age two, which required immuno-regates in the paternal branch of the pedigree; however,
suppressive treatment up to the age of eight. Although thisthis unfortunately was not available for analysis (Fig. 1).
clinical course was considered unusual for a COL(IV)-In proband COZ an in-frame deletion in exon 1
associated disorder, the early onset of proteinuria and(40del24) caused the loss of eight amino acids in the
persistent microhematuria with non-nephrotic protein-signal peptide. He is a 14-year-old boy with microhema-
uria at age 28 prompted a renal biopsy to be performed,turia and mild proteinuria (0.2 to 0.8 g/day) since age
where electron microscopy revealed irregular thinningfour. His renal function is presently normal (creatinine
of the GBM. The father died at 50 and the mother atclearance 86 mL/min/1.73 m2) and he has neither ocular
56 with no sign of renal disease. Her 88-year-old auntsigns nor neurosensorial deafness. The same mutation
had a diagnosis of nephritis but was not biopsied, andwas found in the 46-year-old father, who has had micro-
no data are available on her relatives.and macrohematuria since childhood. He has suffered
In proband DIT we identified a nine-nucleotide dele-
from mild bilateral, high-tone and probably job-induced tion (3321del9) causing the loss of a Ser-Pro-Gly tri-
hypacusis since age 39, and has normal renal function. peptide in the collagenous domain. She is a 32-year-old
No mutation was identified (by either SSCP or sequenc- woman who presented with microhematuria and protein-
ing) in the allele inherited from the mother, who has a uria (0.7 g/day). A renal biopsy performed at age 31
normal urinalysis. revealed short segments of thinning of the GBM and
Proband GST has a heterozygous missense G1198S segmental glomerulosclerosis. At age 32 she was given
change in exon 42. This mutation was absent in a control angiotensin-converting enzyme (ACE) inhibitors as anti-
group of 50 healthy individuals. She is a 39-year-old proteinuric treatment. Renal function is presently nor-
woman with microhematuria (30 RBC/microscopic field), mal. Since she is adopted, no information is available on
her relatives.proteinuria (0.4 g/day) and unimpaired renal function.
Longo et al: Autosomal collagen IV disorders1950
peptide. With the PSORT program (www.expasy.ch/
tools/), an extracellular location of the native protein is
correctly predicted with score 0.820, while for the mutant
protein this score is reduced to 0.370. For this mutation,
therefore, a quantitative effect seems more likely than
the qualitative effect predicted for the other in-frame
mutations.
Three more COL4A3 missense changes with no clear
pathogenic significance were identified (Table 3). Two
were private non-glycine substitutions in the triple-heli-
cal domain, not found even in the extended series of 46
patients nor in the 50 controls. A third variant, Q1495R,
was found in the NC domain. In this case, a glutamine
residue conserved in alpha3(IV) chain of several species
is replaced by an ancestral arginine shared by alpha1(IV)
and alpha5(IV) chains (Fig. 4). This variant was identi-
fied in a sporadic patient and in three families where it
was present in all affected relatives and some healthy
ones as well (data not shown). Two synonymous and one
intronic variants were present each in a single patient.
Finally, we found eight common polymorphisms (Ta-
ble 4), including six previously reported in a different
population [7, 10]. Five affect non-glycine residues in
the triple helical domain, one a glycine as well in the
triple helical domain (G43R [10]), one is located in the
NC, and one is synonymous.
COL4A4 changes
None of these changes are predicted to be null muta-
tions (Tables 5, 6 and 7). A pathogenic role is likely for
the G448S substitution in the triple helical domain found
Fig. 2. Mutation inheritance of the compound heterozygous genotype in proband ZIL, but in none of the 50 controls (Figs. 1
in the PAR family. (A) Single-strand conformational polymorphism
and 3). ZIL is a 35-year-old man with microhematuria(SSCP) pattern of exon 1. Arrow indicates the shifted conformer in the
proband and the mother. (B) Taq1 digestion of exon 37. Fragment size and proteinuria, who has suffered from non-progressive
is indicated in bp on the left. The 206 bp polymerase chain reaction CRF since age 28. His blood creatinine is presently
(PCR) product is digested by Taq I enzyme in two fragments of 141
1.57 mg% and clearance 100 mL/min. A renal biopsy atand 65 bp. The R1037X mutation causes the loss of the Taq I site.
age 28 showed non-specific thickening and splitting of
the GBM. The mutation causes the loss of a StuI restric-
tion site, but since his father died at 66, it could only be
The three in-frame deletions occurred at sites of direct analyzed in his healthy mother and brother. Both tested
DNA repeats in the normal COL4A3 sequence. This may negative. Haplotype analysis showed that the normal
have favored a “polymerase slippage” error (not shown). brother received a different paternal allele (not shown).
Our identified mutations are likely to have various func- Three other private missense changes were non-gly-
tional consequences (Fig. 3). The glycine substitution cine substitutions and their pathogenic role remains to
(G1198S) and the two in-frame deletions in collagenous be established (Table 6). R877Q and P1257R affect the
domain (3321del9 and 3386del27) are expected to pro- triple helical domain. The third substitution, I967V, falls
duce abnormal chains that can be incorporated into ab- within the eighteenth interruption of the collagenous
normal tropocollagen monomers. By contrast, the frame- domain. Thirteen additional COL4A4 variants were con-
shift (3209insA) and stop codon (R1037X) are null muta- sidered as polymorphisms. Four of these—two previ-
tions. The same is true for the start codon mutation ously characterized by Boye et al [9] and two first reported
(M1L), since the next methionine is localized in exon here—result in amino acid substitutions in the triple
11, 208 amino acids downstream, and no upstream methi- helical domain, while six—comprising the GGG→GGA
onine codon can be found before a stop at 16. Finally, polymorphism at codon 1198 in exon 39 [11]—were syn-
a strongly reduced secretion of the protein is expected onymous changes. The other three were novel intronic
polymorphisms.for the in-frame deletion (40del24) affecting the signal
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Table 2. Mutations in the COL4A3 gene
Exon Mutation Nucleotide change Effect on coding sequence Predicted effect on protein Proband
1 M1L c.1 AT Met→Leu at 1 Unknowna PAR
1 40del24 Deletion of 24 bp Deletion of 8 amino acids Reduced production COZ
at c.40 (from 14) in signal peptide
37 R1037X c.3109 CT Arg1037→Stop Termination at 1037 PAR
37 3209insA Insertion of A Frame-shift Termination at 1078 NCL
at c.3209
38 3321del9 Deletion of 9 bp Deletion of 3 amino acids Chain shortening DIT
at c.3321 (from 1107) in the CD
39 3386del27 Deletion of 27 bp Deletion of 9 amino acids Chain shortening NCL
at c.3386 (from 1129) in the CD
42 G1198S c.3592 GA Gly1198→Ser in the CD Interruption of continuous Gly-X-Y GST
CD is collagenous domain.
a Likely p0 as there is no alternative downstream AUG codon
Table 3. Rare variants of unknown significance in the COL4A3 gene
Frequency
Exon Variant Nucleotide change Effect on coding sequence Patients Controls Reference
23 G484G c.1452 GA Synonymous Gly 484 1/46 0/50 This study
38 P1109S c.3325 CT Pro1109→Ser in the CD 1/46 0/50 This study
34 P942P c.2987 CT Synonymous Pro 942 1/46 0/50 This study
46 D1347E c.4041 CA Asp1347→Glu in the CD 1/46 0/50 [10]
49 Q1495R c.4645 AG Gln1495→Arg in the NCD 4/46 0/50 This study
48(IVS) g.4463–11 AT g.4463–11 AT — 1/46 0/50 This study
Abbreviations are: CD, collagenous domain; NCD, non-collagenous domain.
Table 4. Polymorphisms in the COL4A3 gene
Exon Variant Nucleotide change Effect on coding sequence Heterozygosity Restriction enzyme Reference
2 G43R c.127 CG Gly→Arg at 43 in the first Gly of CD 0.4 MspI [10]
7 P141L c.422 CT Pro→Leu at 141 in the CD 0.23 BsrI This study
9 E162G c.485 AG Glu→Gly at 162 in the CD 0.25 EcoNI [10]
17 D326Y c.976 GT Asp→Tyr at 976 in the CD 0.1 MboII [10]
21 L399L c.1195 TC Synonymous Leu 399 in the CD 0.1 — This study
21 R408H c.1223 GA Arg→His at 408 in the CD 0.1 Fnu4HI [10]
22 H451R c.1352 AG His→Arg at 451 in the CD 0.1 BstUI [10]
48 L1474P c.4421 TC Leu→Pro at 1474 in the NCD 0.1 — [7, 10]
DISCUSSION In view of these ascertainment ambiguities, we adopted
rather permissive inclusion criteria in the study of auto-Alport syndrome may be caused by mutations in any of
somal ATS, as in our previous study of X-linked ATSthree COL4A3, COL4A4, or COL4A5 genes encoding
[3]. Together with cases displaying typical features oftissue-specific collagen IV chains. Since 1990 extensive
recessive ATS, that is, rapidly sex-independent progres-studies of COL4A5 in the common X-linked semidomi-
sive nephritis or parental consanguinity [8–10], we in-nant ATS type have characterized more than 300 muta-
cluded sporadic male and female patients who had testedtions and identified the genotype-phenotype correlation
negative for COL4A5 mutations. Our two-step analysis[15–18]. More limited studies have implicated COL4A3
of COL4A3 and COL4A4 identified many changes, onlyand COL4A4 in autosomal-recessive [7–10, 19–23] and
eight of which could be confidently considered patho-autosomal-dominant ATS [12, 13], as well as in BFH
genic. None was in homozygous state, which would have[9–11]. The wide phenotypic spectrum of collagen IV dis-
been useful to evaluate their role. In COL4A3, four mu-orders, the several underlying loci, and mutational heter-
tations were found in compound heterozygotes and threeogeneity make molecular diagnosis difficult, particularly
in simple heterozygotes, as the single COL4A4 mutation.in small families and sporadic cases, where formal genetic
In COL4A3, the start codon- and nonsense changesanalysis fails to suggest what gene to study and what
(proband PAR) as well as the frame-shift (maternal mu-genotype to expect (homozygous/genetic compound vs.
heterozygous). tation in NCL) likely result in complete loss of function.
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Table 5. Mutations in the COL4A4 gene
Exon Mutation Nucleotide change Effect on coding sequence Predicted effect on protein Proband
20 G448S c.1550 GA Gly→Ser at 448 Interruption of continuous ZIL
Gly-X-Y
Table 6. Rare variants of unknown significance in the COL4A4 gene
Frequency
Exon Variant Nucleotide change Effect on coding sequence Patients Controls
14(IVS) 871  18 ins T Insertion of T at — 1/46 0/50
g.871  18
30 R877Q c.2838 GA Arg→Gln in the CD 1/46 0/50
32 I967V c.3107 AG Ile→Val in interruption 1/46 0/50
XVIII
32 G975G c.3133 GA Synonymous Gly 975 1/46 0/50
40 P1257R c.3978 CG Pro→Arg in the CD 1/46 0/50
All data are from the current study.
Table 7. Polymorphisms in the COL4A4 gene
Nucleotide Effect on coding Restriction
Exon Variant change sequence Heterozygosity enzyme Reference
17 (IVS) 1029  36 AC c.1029  36 AC — 0.1 — This studyc
18 L365L c.1303 TC Synonymous Leu 0.3 MseI This study
365
21 P482S c.1652 CT Pro→Ser at 482 in 0.4 HaeIII [9]a
the CD
23 G545A c.1842 GC Gly→Ala at 545 0.1 SphI [9]b
in the CD
28 (IVS) 2592-5 CT g.2592-5 CT — 0.1 DdeI [9]a
33 L1004P c.3219 TC Leu→Pro at 1004 0.4 MspI [9]b
in the CD
39 G1198G c.3802 GA Synonymous Gly 0.4 HaeIII [11]
1198
K1228K c.3892 GA Synonymous Lys 0.1 — [9]a
1228
42 P1360P c.4288 AG Synonymous Pro 0.1 HpaII [9]a
1360
M1327V c.4190 AG Met→Val at 1327 0.1 BsrI [9]a
in the CD
47 V1516V c.4753 AG Synonymous Val 0.5 — [9]a
1516
46 (IVS) 4731-8TC g.4731-8 TC — 0.5 — [9]a
48 F1644F c.5140 CT Synonymous Phe 0.3 — This study
1644
a Cited by Boye et al and characterized here
b Polymorphisms characterized by Boye et al and confirmed in this study
c This study, first described here
In agreement with this prediction, the pattern of inheri- gen triple helix. This strongly supports their pathogenic-
ity, and even suggests a dominant negative effect. Thetance in these families is recessive, as mothers of PAR
and NCL are asymptomatic, and the father of PAR has same mechanism can be ascribed, by analogy with the
model of osteogenesis imperfecta [24, 25], to the two mis-isolated microhematuria. A similar mild BFH phenotype
in COL4A3 heterozygotes has been reported by Heidet sense changes affecting glycine residues in the collage-
nous domain of the alpha3(IV) chain in GST, and theet al [10]. A different pathogenic mechanism is likely for
two in-frame deletions in the collagenous domain (DIT alpha4(IV) chain in ZIL. Since three of the four parents
were already dead, inheritance could not be demonstrated.and paternal mutation in NCL), predicted to result in
the synthesis of shortened but NC domain-retaining Even so, both mutations are probably dominant since
no change in the second allele was detected by sequenc-alpha(IV) chains that may be incorporated in the colla-
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Fig. 3. Distribution of pathogenic mutations along the genes COL4A4 (top) and COL4A3 (bottom). Gray boxes denote mutations found in
recessive phenotypes and striped boxes are mutations found in dominant phenotypes.
Fig. 4. Evolutionary conservation at codon
1495 of the alpha3(IV) chain. In the box is the
corresponding position in the human COL4A1
and COL4A5 genes and COL4A3 of other
species. The Q1495R variant substitutes an
ancestral arginine residue for an alpha3(IV)-
specific glutamine.
ing all PCR products of the relevant gene. Moreover, a progression to CRF reported in the family of autosomal-
dominant ATS caused by a COL4A3 mutation [13].diagnosis of BFH was ruled out in both patients by the
presence of proteinuria, which was absent in the null A tentative genotype-phenotype correlation is shown
in Figure 3. Mutations are classified in two groups ex-mutation carriers. If our interpretation is correct, pro-
band ZIL is the first example of autosomal-dominant pected to either cause the production of an abnormal
alpha-chain or reduce its synthesis, and operationally di-ATS caused by a COL4A4 mutation. His renal function
is still preserved at age 35, in agreement with the very late vided according to whether they are present alone (prob-
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ably autosomal dominant), or belong to compound het- state and their fraction in COL4A3/COL4A4 is largely
unknown.erozygous genotypes (probably autosomal recessive). In
recessive cases, both null- and abnormal-chain mutations The high level of polymorphism in both autosomal
genes is an additional difficulty in recognizing mutationsare found, whereas the dominant inheritance seems lim-
ited to mutations predicted to result in the production by SSCP, which was not encountered in the analysis of
COL4A5 on the X chromosome. Under some circum-of an abnormal chain. This is in agreement with the only
reported patient with autosomal-dominant ATS, who stances, however, polymorphisms even contributed to the
analysis, such as by excluding extended heterozygous dele-had a large in-frame deletion of the alpha 3(IV) chain,
resulting from the skipping of exon 21 [13]. Although tions. The confounding occurrence of polymorphisms was
partly reduced by using internal primers [9], though thisno other family with a clear autosomal-dominant inheri-
tance and a COL(IV) mutation has been reported, Heidet excluded part of the coding sequence and some exon-
intron junctions.et al mentioned a father heterozygous for the G297E
mutation who reached ESRD at the age of 40 [10]. Several polymorphisms, previously noted but not se-
quenced in COL4A4 by Boye et al [9], were further char-It should be noted that the phenotype severity of carri-
ers of mutations resulting in abnormal alpha(IV) chains acterized. Of the 13 polymorphisms scattered over the
entire gene, three were intronic and six resulted in synon-did not clearly follow the biochemical predictions. Thus,
the in-frame deletion in the signal peptide (40del24 in ymous changes. For some of them an adverse effect on
splicing cannot be ruled out: for example, P1360P infamily COZ), predicted to strongly reduce secretion of
the protein, was associated with a severe phenotype in exon 42 may have an influence by replacing the adenine
two nucleotides upstream from the splice site. Similarly,both the heterozygous father and son, which indicates
autosomal dominant inheritance. In contrast with the the rare G975G variant identified in one patient may af-
fect splicing by introducing a potential AG donor signalpredicted dominant effect, one of the in-frame deletions
(3386del27 in family NCL) was recessively inherited, as within exon 32 (GGGGAA→GGAGAA). The COL4A3
gene was highly polymorphic as well, but displayed ashown by the severe phenotype of the genetic compound
daughter and the milder one of the heterozygous father. different pattern: only one polymorphism was synony-
mous, while most resulted in amino acid substitutions.Testing larger series of patients will be necessary to as-
certain whether penetrance in heterozygotes indeed Evaluating the pathogenic significance of missense
changes was particularly difficult in this study. Substitu-may be confined to dominant negative mutations, and
whether phenotype severity (as in osteogenesis imper- tions of glycine residues in the collagenous domain of
COL4A5 are considered as pathogenic through a domi-fecta [24, 25]) correlates with the type and position of
the change and/or with other interacting factor(s). nant negative mechanism, and are the most common
missense mutations in that gene. Even they, however,In view of these findings, we could reach a positive
diagnosis only in six out of the 36 families. Our rate of showed less predictable effects in the autosomal colla-
gen IV genes. Glycine changes in the alpha3(IV) andidentified pathogenic mutations (11% of the alleles) is
much lower than the 53% reported by Heidet et al [10], alpha4(IV) chains have been reported both as causative
mutations in autosomal recessive ATS [9, 10] and BFHthough their patients were highly selected.
Identification of few mutations in this study may depend [11], and as common non-pathogenic polymorphisms:
G43R in COL4A3 [10] and G545A in COL4A4 [9]. Theon both the relaxed selection criteria and limited analytical
sensitivity, especially critical for autosomal ATS, where high frequency of these variants in our healthy controls
shows that they should be considered as common poly-the immunohistochemical testing of skin, useful in X-linked
ATS [26], is precluded by lack of expression of alpha3 morphisms. G43R may exert a mild influence on chain
flexibility since it affects the first glycine of the collage-(IV) and alpha4(IV) chains in normal skin.
The fact that direct sequencing revealed two addi- nous domain.
By contrast, six other COL4A3 variants could not betional mutations overlooked by SSCP demonstrates that
limited analytical sensitivity is to some extent responsible. assumed to be pathogenic on biochemical grounds (Ta-
ble 3), but were indirectly imputed by their absence inThe same limitation also affected our previous COL4A5
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